Antifungal activity of miconazole against recent Candida strains

Miconazole (MICON) has long been used for the topical treatment of mucosal candidiasis. However, the preponderance of MICON susceptibility data was generated before standard methodology was established, and prior to the emergence of fluconazole (FLU)‐resistant strains. The objective of this study was to determine the antifungal activity of MICON and comparators against recent clinical isolates of Candida spp. using standard Clinical and Laboratory Standards Institute methodology. One hundred and fifty isolates, consisting of 25 strains each of Candida albicans, C. krusei, C. glabrata, C. tropicalis, C. parapsilosis and C. dubliniensis, were tested. Of these, twenty‐two strains were known to be FLU‐resistant. Minimum inhibitory concentrations (MICs) were determined for MICON, amphotericin B (AM), caspofungin (CAS), clotrimazole (CLOT), FLU, itraconazole (ITRA), nystatin (NYS) and voriconazole (VOR). MICON demonstrated potent inhibitory activity against all of the strains tested. The MIC90 for MICON was 0.12 μg ml−1 against FLU‐susceptible strains, which was comparable to that of AM, CAS, CLOT, ITRA and VOR. The MICON MIC90 against FLU‐resistant strains was 0.5 μg ml−1, which was 12‐fold lower than the FLU MIC90. Our study showed that MICON possesses potent activity against all of the Candida isolates tested, including those with known FLU resistance. This indicates that recent clinical isolates remain susceptible to this antifungal and that MICON could be used as first‐line treatment for oropharyngeal candidiasis.

[1]  M. Moshi,et al.  Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis , 2008, BMC Microbiology.

[2]  C. Fichtenbaum,et al.  A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis , 2008, Journal of acquired immune deficiency syndromes.

[3]  S. Chunchanur,et al.  Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients. , 2008, The Southeast Asian journal of tropical medicine and public health.

[4]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[5]  T. Young,et al.  Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. , 2010, The Cochrane database of systematic reviews.

[6]  M. Ruhnke,et al.  Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. , 2006, Current drug targets.

[7]  M. Bassetti,et al.  Epidemiological trends in nosocomial candidemia in intensive care , 2006, BMC infectious diseases.

[8]  L. McDonald,et al.  Colonization of Human Immunodeficiency Virus-Infected Outpatients in Taiwan with Candida Species , 2005, Journal of Clinical Microbiology.

[9]  S. Redding,et al.  The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. , 2000, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[10]  J. Vazquez,et al.  Therapeutic Options for the Management of Oropharyngeal and Esophageal Candidiasis in HIV/AIDS Patients , 2000, HIV clinical trials.